Search Result

Results for "

LDH

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Lactate Dehydrogenase (45) 5-HT Receptor (1) AIM2 (1) Akt (10) Aldehyde Dehydrogenase (ALDH) (1) Aminotransferases (Transaminases) (1) AMPK (1) Amyloid-β (1) Apoptosis (21) Atg8/LC3 (1) ATP Synthase (1) Autophagy (1) Bacterial (3) Bcl-2 Family (4) Biochemical Assay Reagents (3) Calcium Channel (11) Cannabinoid Receptor (1) Caspase (10) Cholinesterase (ChE) (3) COX (2) Dipeptidyl Peptidase (2) DNA/RNA Synthesis (1) Drug Derivative (3) Drug Metabolite (1) EGFR (1) Endogenous Metabolite (5) Environmental Pollutants (1) ERK (1) Ferroptosis (8) Formyl Peptide Receptor (FPR) (1) FOXO (1) GSK-3 (1) HBV (8) HIV (1) IAP (1) Interleukin Related (6) Isotope-Labeled Compounds (7) JNK (2) MDM-2/p53 (2) MMP (1) nAChR (1) Necroptosis (1) Neuropeptide Y Receptor (1) NO Synthase (1) NOD-like Receptor (NLR) (3) Opioid Receptor (1) Oxidative Phosphorylation (1) p38 MAPK (2) p62 (1) Parasite (6) PI3K (10) Prostaglandin Receptor (1) PROTACs (1) Pyroptosis (5) Reactive Oxygen Species (ROS) (19) Reference Standards (8) RIP kinase (1) Small Interfering RNA (siRNA) (2) SOD (5) TNF Receptor (3)
By Research Areas:	Cancer (27) Cardiovascular Disease (13) Endocrinology (1) Infection (11) Inflammation/Immunology (15) Metabolic Disease (21) Neurological Disease (13)
Click Chemistry:	PROTAC Synthesis (1)
Oligonucleotides:	siRNA drugs (2) siRNAs (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

MCE Kits

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Lactate Dehydrogenase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W013032A

Oxamic acid sodium Maximum Cited Publications 58 Publications Verification Sodium oxamate	Lactate Dehydrogenase Apoptosis	Cancer
Oxamic acid (oxamate) sodium salt is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid sodium salt shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .

HY-W013032

Oxamic acid Maximum Cited Publications 58 Publications Verification Oxamidic acid	Lactate Dehydrogenase Apoptosis	Cancer
Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .

HY-W040118

Galloflavin 10+ Cited Publications	Lactate Dehydrogenase	Cancer
Galloflavin is a potent lactate dehydrogenase *(LDH)* inhibitor. The calculated K_is for pyruvate are 5.46 μM (LDH-A) and 15.06 μM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production .

HY-113308

Taurolithocholic acid 5+ Cited Publications	Calcium Channel Ferroptosis PI3K Akt HBV Reactive Oxygen Species (ROS)	Cardiovascular Disease Infection Inflammation/Immunology
Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis (Ferroptosis), viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and *LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV* infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .

HY-W040073

Nifurtimox 1 Publications Verification	Parasite Lactate Dehydrogenase	Infection Cancer
Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).

HY-113308A

Taurolithocholic acid sodium salt 5+ Cited Publications	Calcium Channel Ferroptosis PI3K Reactive Oxygen Species (ROS) Akt HBV	Metabolic Disease
Taurolithocholic acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and *LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium salt not only protects mice from lethal SFTSV* infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .

HY-P10408

Candidalysin	EGFR MMP Calcium Channel NOD-like Receptor (NLR) ERK p38 MAPK	Infection Inflammation/Immunology
Candidalysin is a cytolytic peptide toxin secreted by the fungus Candida albicans. Candidalysin drives epithelial immune responses by activating the EGFR-MAPK signaling pathway, inducing MMP expression and calcium influx, and regulating the c-Fos transcription factor and MKP1 via p38 MAPK and ERK1/2 respectively. Candidalysin is essential for mucosal and systemic infections, activating NLRP3 to promote inflammatory responses, neutrophil recruitment, and Th17 immunity. Candidalysin activates *LDH* causing membrane damage and exhibiting cytotoxicity

HY-P2807F

*Lactate Dehydrogenase (LDH), Bovine Heart* LAD, LD, L-LDH, (S)-Lactate: NAD+ oxidoreductase	Lactate Dehydrogenase	Cardiovascular Disease
Lactate Dehydrogenase (LDH), Bovine Heart (LAD) is an oxidoreductase that catalyzes the reversible conversion between lactate and pyruvate. Lactate Dehydrogenase (LDH), Bovine Heart is mainly used in life science research, tissue damage diagnosis, and as an enzyme marker .

HY-111108

LDH-IN-1 2 Publications Verification	Lactate Dehydrogenase	Cancer
LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase *(LDH)* with IC₅₀s of 32 and 27 nM for LDHA and LDHB, respectively.

HY-113486

Lathosterol 2 Publications Verification	Endogenous Metabolite SOD Lactate Dehydrogenase	Metabolic Disease
Lathosterol is a plant sterol and cholesterol-like molecule. Lathosterol increases antioxidant enzymes (such as SOD, CAT, and GSH) and decreases *LDH*. Lathosterol has a hepatoprotective effect on mice with acetaminophen (HY-66005)-induced liver injury ^{[1] .}

HY-132606A

Nedosiran sodium DCR-PHXC sodium	Small Interfering RNA (siRNA) Lactate Dehydrogenase	Metabolic Disease
Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran sodium is a GalNAc-dsRNA conjugate .

HY-P2897

D-Lactate dehydrogenase, Microorganism 1 Publications Verification D-LDH	Lactate Dehydrogenase	Others
D-Lactate dehydrogenase, Microorganism (D-LDH) is an oxidoreductase that uses NAD ⁺ or NADP ⁺ as an acceptor and acts on the donor CH-OH group, and can catalyze the oxidation of D-lactate to pyruvate. D-Lactate dehydrogenase widely exists in bacteria and fungi, and is often used in biochemical research .

HY-152670

JC2-11 1 Publications Verification	NOD-like Receptor (NLR) AIM2	Inflammation/Immunology
JC2-11 is an inhibitor of inflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4, absent in melanoma 2 (AIM 2) and non-canonical (NC) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 (p20), the cleavage of gasdermin D (GSDMD), and the releases of IL-1β and lactate dehydrogenases (LDH) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1 .

HY-N7393

Isomalt Palatinitol	Environmental Pollutants Lactate Dehydrogenase	Metabolic Disease
Isomalt (Palatinitol), a well-tolerated, non-toxic polyol and a protein-stabilizing excipient, stabilizes lactate dehydrogenase (LDH) moderately during freeze-drying, and performs better during storage. Isomalt is traditionally used as a sweetening agent in the food industry and as a tabletting excipient for pharmaceutical purposes .

HY-P3509

PNC-28	MDM-2/p53	Cancer
PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research .

HY-P2807A

*Lactate Dehydrogenase (LDH), Porcine Heart* LDH, Lactic Dehydrogenase	Biochemical Assay Reagents	Cardiovascular Disease
Lactate Dehydrogenase (LDH), Porcine Heart, is an isoenzyme of lactate dehydrogenase derived from porcine heart. Lactate Dehydrogenase (LDH), Porcine Heart, is primarily used in life science research, tissue damage diagnosis, and as an enzyme marker .

HY-152261

MS6105	PROTACs	Cancer
MS6105 is an *LDH* protein hydrolysis-targeted chimera (PROTAC) that effectively degrades LDHA and LDHB in a time- and ubiquitin-proteasome system-dependent manner and has anticancer activity . MS6105 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-124546

Necrostatin-5 1 Publications Verification Nec-5	Necroptosis RIP kinase	Neurological Disease
Necrostatin-5 (Nec-5) is a potent necroptosis inhibitor with an EC₅₀ value of 0.24 µM. Necrostatin-5 also is a RIP1 inhibitor. Necrostatin-5 shows cardioprotective effects .

HY-103348

Boc-Asp(OMe)-fluoromethyl ketone Boc-Asp(OMe)-FMK	Caspase	Inflammation/Immunology
Boc-Asp(OME)-Fluoromethyl Ketone is a broad range caspase inhibitor that inhibits Fas-mediated phagocytosis and oxidative rupture inhibition, but does not affect the chemotactic activity of IL-8 .

HY-34154

4-(Dimethylamino)phenol	Lactate Dehydrogenase	Others
4-(Dimethylamino)phenol is a potent cyanide antidote. 4-(Dimethylamino)phenol increases the extracellular lactate dehydrogenase (LDH) without markedly affecting gluconeogenesis. 4-(Dimethylamino)phenol cannot decreases the ATP content until the membrane becomes permeable to LDH. 4-(Dimethylamino)phenol’s toxicity is related to its reaction with glutathione and formation of covalent complexes, leading to impaired cellular function .

HY-120553

B-355252 1 Publications Verification	Apoptosis	Neurological Disease
B355252, a phenoxy thiophene sulfonamide small molecule, is a potent NGF receptor agonist. B355252 potentiates NGF-induced neurite outgrowth. B355252 protects ischemic neurons from neuronal loss by attenuating DNA damage, reducing ROS production and the LDH level, and preventing neuronal apoptosis. B355252 has anti-apoptotic effects in glutamate-induced excitotoxicity, as well as in a murine hippocampal cell line (HT22) model of Parkinson disease (PD) .

HY-131485

3-Acetylpyridine adenine dinucleotide, 90% 3-APAD, 90%; 3-Acetylpyridine NAD, 90%	Lactate Dehydrogenase	Metabolic Disease
3-Acetylpyridine adenine dinucleotide, 90% is an analog of nicotinamide adenine dinucleotide (NAD). 33-Acetylpyridine adenine dinucleotide, 90% collaboratively inhibits Lactate Dehydrogenase (LDH) with bisulfite .

HY-176798

NCI-006	Lactate Dehydrogenase Reactive Oxygen Species (ROS) Apoptosis	Cancer
NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC₅₀ = 0.06 μM; LDHB IC₅₀ = 0.03 μM). NCI-006 inhibits intratumoral *LDH* activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .

HY-153129

EP2 receptor antagonist-2	Prostaglandin Receptor	Endocrinology
EP2 receptor antagonist-2 (CID891729) is an antagonist of EP2 receptor. EP2 receptor antagonist-2 inhibits the EP2 receptor activation induced by PGE2. EP2 receptor antagonist-2 also suppresses lactate dehydrogenase (LDH) release induced by N-methyl-D-aspartate (NMDA) .

HY-P3509A

PNC-28 acetate	MDM-2/p53	Cancer
PNC-28 acetate is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 acetate can be used for pancreatic cancer research .

HY-P10939A

Ac-DMLD-CMK TFA	Caspase Pyroptosis	Inflammation/Immunology Cancer
Ac-DMLD-CMK TFA is a caspase 3 inhibitor and a GSDME inhibitor. Ac-DMLD-CMK TFA binds directly to the catalytic domain of caspase-3, blocks caspase-3-mediated cleavage of GSDME, inhibits the activation of caspase 3 and Gsdme in the caspase 3-Gsdme signaling pathway, and reduces the levels of pyroptosis and apoptosis as well as the expression of LDH, IL-6, IL-1β and IL-18. Ac-DMLD-CMK TFA alleviates renal function deterioration, renal tubular epithelial cell injury, inflammatory cytokine secretion, pulmonary structural damage, and chemotherapy-induced nephrotoxicity .

HY-N5073

Vitexin-4''-O-glucoside 4''-O-Glucosylvitexin	JNK p38 MAPK Interleukin Related TNF Receptor Caspase Lactate Dehydrogenase Apoptosis	Cardiovascular Disease Metabolic Disease
Vitexin-4''-O-glucoside (4''-O-Glucosylvitexin) is an orally active natural flavonoid component with multiple pharmacological effects including antioxidation, anti-inflammation, cytoprotection and anti-apoptosis. Vitexin-4''-O-glucoside regulates the MAPK signaling pathway by downregulating the phosphorylation levels of JNK and p38, thereby blocking endoplasmic reticulum stress responses. Vitexin-4''-O-glucoside alleviates oxidative stress by reducing MDA content and upregulating the activities of SOD and CAT, attenuates inflammation by downregulating the expressions of inflammatory factors TNF-α, IL-1β and IL-6, and also reduces *LDH* release and inhibits caspase-3 activation. Vitexin-4''-O-glucoside effectively improves drug-induced acute liver injury and exerts significant protective effects against myocardial hypoxia/reoxygenation injury. Vitexin-4''-O-glucoside can be used in studies on acute liver injury, cardiovascular diseases and myocardial hypoxia-reoxygenation injury .

HY-171944

6-O-Oleoyltrehalose	Drug Derivative Lactate Dehydrogenase	Others
6-O-Oleoyltrehalose is a derivative of trehalose. 6-O-Oleoyltrehalose has biodegradable and low surface tension reduction ability. 6-O-Oleoyltrehalose preserves Lactate dehydrogenase (LDH) activity during freeze/thaw cycles. 6-O-Oleoyltrehalose can be used for stabilizer research .

HY-P2768

Leucine dehydrogenase, Microorganism LDH, EC 1.4.1.9	Endogenous Metabolite	Metabolic Disease
Leucine dehydrogenase, Microorganism (EC 1.4.1.9) can be purified from Bacillus spheroides. Leucine dehydrogenase catalyzed the oxidative deamination of L-leucine, L-valine, L-isoleucine, L-norvaline, L-alpha-aminobutyrate, and L-norleucine, and the reductive amination of their keto analogues .

HY-132606

Nedosiran DCR-PHXC	Small Interfering RNA (siRNA) Lactate Dehydrogenase	Metabolic Disease
Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate .

HY-N2177

3-Dehydrotrametenolic acid	Lactate Dehydrogenase Apoptosis	Cancer
3-Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-Dehydrotrametenolic acid induces apoptosis and has anticancer activity .

HY-129101

(-)-Eseroline fumarate Eseroline fumarate	5-HT Receptor	Neurological Disease
(-)-Eseroline fumarate is a metabolic of Physostigmine (HY-N6608), an AChE inhibitor. (-)-Eseroline fumarate elicits a leakage of lactic acid dehydrogenase (LDH) from cancer cells. (-)-Eseroline fumarate also induces the release of adenine nucleotides and 5-hydroxytryptamine (5-HT) from neuronal cells, thus induce cell death. (-)-Eseroline fumarate inhibits the electrically evoked twitches of the mouse vas deferens and of the guinea-pig ileum .

HY-130502

5β,6β-Epoxycholestanol Cholesterol 5β,6β-epoxide; 5β,6β-Epoxycholesterol	Apoptosis	Inflammation/Immunology Cancer
5β,6β-epoxycholestanol (Cholesterol 5β,6β-epoxide; 5β,6β-Epoxycholesterol) is an oxysterol. 5β,6β-epoxycholestanol induces cytotoxicity in bronchial epithelial cells. 5β,6β-epoxycholestanol induces lactate dehydrogenase (LDH) release and apoptosis in lymphoma cells undergoing macrophage differentiation . 5β,6β-epoxycholestanol is applicable to research related to atherosclerosis .

HY-P10939

Ac-DMLD-CMK	Caspase Pyroptosis	Inflammation/Immunology Cancer
Ac-DmLD-CMK is a caspase 3 inhibitor and a GSDME inhibitor. Ac-DmLD-CMK binds directly to the catalytic domain of caspase-3, blocks caspase-3-mediated cleavage of GSDME, inhibits the activation of caspase 3 and Gsdme in the caspase 3-Gsdme signaling pathway, and reduces the levels of pyroptosis and apoptosis as well as the expression of LDH, IL-6, IL-1β and IL-18. Ac-DmLD-CMK alleviates renal function deterioration, renal tubular epithelial cell injury, inflammatory cytokine secretion, pulmonary structural damage, and chemotherapy-induced nephrotoxicity .

HY-N10131

Biatractylolide (+)-Biatractylolide	Apoptosis	Neurological Disease Cancer
Biatractylolide is a compound isolated from the ethyl acetate extract of Atractylodes macrocephala. Biatractylolide has antitumor and antioxidant activities. Biatractylolide improves cell viability, inhibits the apoptosis of cells induced by glutamate, and reduces the activity of LDH. Biatractylolide has neuroprotective effects .

HY-P2807G

*Lactate Dehydrogenase (LDH), Chicken Heart* LAD, LD, L-LDH, (S)-Lactate, LDH	Lactate Dehydrogenase	Others
Lactate Dehydrogenase (LDH), Chicken Heart (LAD, LD, L-LDH, (S)-Lactate, LDH) is a biological material or organic compound that can be used in life science research .

HY-113308S1

Taurolithocholic acid-d4	Isotope-Labeled Compounds Calcium Channel Ferroptosis PI3K Reactive Oxygen Species (ROS) Akt HBV	Others
Taurolithocholic acid-d₄ is deuterium labeled Taurolithocholic acid. Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and *LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV* infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .

HY-148610

LDH-IN-2	Others	Metabolic Disease
LDH-IN-2, a salicylic acid derivative, is an inhibitor of glycolate oxidase (GO). LDH-IN-2 decreases oxalate output in hyperoxaluric hepatocytes. LDH-IN-2 can be used for research of primary hyperoxaluria type 1 (PH1) .

HY-P2807J

*L-Lactate Dehydrogenase (L-LDH), pig muscle*	Lactate Dehydrogenase	Metabolic Disease
L-Lactate Dehydrogenase (L-LDH), pig muscle is an L-lactate dehydrogenase found in pig muscle, mainly present in anaerobic tissues (skeletal muscle, red blood cells). L-Lactate Dehydrogenase (L-LDH), pig muscle can interact with acidic liposomes at low pH, causing protein to adsorb onto the liposomes and inhibit enzyme activity. The IC₅₀ values for L-Lactate Dehydrogenase (L-LDH), pig muscle are 0.05 μM for cardiolipin and 1.3 μM for phosphatidylserine liposomes .

HY-N16650

Bisadinrone A	Lactate Dehydrogenase	Cardiovascular Disease
Bisadinrone A is a sesquiterpene found in Curcuma longa. Bisadinrone A can inhibit *LDH* release and shows significant anti-myocardial ischemia-reperfusion injury activity. Bisadinrone A can be used for the research of cardiovascular disease, such as ischemic heart disease .

HY-151243

NCATS-SM1441	Lactate Dehydrogenase	Cancer
NCATS-SM1441 (compound 52) is a lactate dehydrogenase (LDH) inhibitor (IC₅₀=40 nM). By inhibiting the activity of *LDH*, NCATS-SM1441 is able to reduce the production of lactic acid in cancer cells, helping to slow or stop the proliferation of cancer cells. NCATS-SM1441 can be used to study cancer metabolism .

HY-172529

DPP9-IN-1	Dipeptidyl Peptidase	Neurological Disease Metabolic Disease
DPP9-IN-1 (Compound 42) is a dipeptidyl peptidase 9 (DPP9) inhibitor with IC₅₀ of 3 nM for DPP9 and 0.6 μM for DPP8. DPP9-IN-1 induces concentration-dependent LDH release in THP-1 cells .

HY-139182

MAGL-IN-3	Endogenous Metabolite	Metabolic Disease
CAY10762 is an inhibitor of monoacylglycerol lipase (MAGL; IC₅₀=34.1 nM). It reduces hydrogen peroxide-induced lactate dehydrogenase (LDH) release from Neuro2a cells when used at a concentration of 1 μM. CAY10762 (10 mg/kg) increases levels of 2-arachidonoyl glycerol in mouse brain.

HY-131829

N6-(2-Aminoethyl)-NAD+ 6-AE-NAD+	Biochemical Assay Reagents	Others
N6-(2-Aminoethyl)-NAD+ (6-AE-NAD+) is a NAD+ derivative commonly used in affinity chromatography. N6-(2-Aminoethyl)-NAD+ can be covalently linked to a PQQ (pyrroloquinoline quinone) (HY-100196) monolayer on an electrode surface for immobilizing NAD+-dependent enzymes such as lactate dehydrogenase (LDH) .

HY-N2891

Aristolactam A II Aristololactam A II	Parasite COX	Infection
Aristolactam A II (Aristololactam A II) is a weak COX inhibitor with cytotoxic and anti-plasmodial activities. Aristolactam A II exhibits inhibitory activity against Chloroquine (HY-17589A)-sensitive strains, and exerts its inhibitory effect on Plasmodium falciparum growth by inducing cell membrane damage marked by LDH release. Aristolactam A II can be applied to the research of malaria-related mechanisms .

HY-178943

Neuroprotective agent 15	Cholinesterase (ChE) Cannabinoid Receptor Aldehyde Dehydrogenase (ALDH) Caspase Apoptosis	Neurological Disease
Neuroprotective agent 15 (Compound 3e) is a neuroprotective agent. Neuroprotective agent 15 is a selective butyrylcholinesterase (BChE) inhibitor, with IC₅₀ values of 2.6 and 114.3 μM for BChE and AChE respectively. Neuroprotective agent 15 has cannabinoid CB2 receptor (CB2 receptor) agonistic activity. Neuroprotective agent 15 can reduce cell death, *LDH* release and Caspase-3/7 activity, and inhibit apoptosis. Neuroprotective agent 15 can reduce the formation of superoxide free radicals, maintain cell morphology, and significantly lower oxidative stress levels. Neuroprotective agent 15 can be used in the research of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease .

HY-175640

Troponin-IN-1	Pyroptosis Reactive Oxygen Species (ROS) Interleukin Related Caspase	Cardiovascular Disease
Troponin-IN-1 is a troponin inhibitor. Troponin-IN-1 protects OGD/R-injured H9c2 cardiomyocytes by reducing LDH leakage, pyroptosis and ROS accumulation. Troponin-IN-1 inhibits NO production and IL-1β/TNF-α/IL-18 release in LPS (HY-D1056)-induced RAW264.7 cells. Troponin-IN-1 acts via caspase-1/GSDMD/IL-18 pathway. Troponin-IN-1 reduces myocardial infarct size in LAD-induced myocardial ischemia/reperfusion (MI/R) male rats. Troponin-IN-1 can be used for the study of myocardial ischemia/reperfusion (MI/R) injury .

HY-113308AR

Taurolithocholic acid sodium salt (Standard)	Reference Standards Calcium Channel Ferroptosis PI3K Reactive Oxygen Species (ROS) Akt HBV	Metabolic Disease
Taurolithocholic acid (sodium salt) (Standard) is the analytical standard of Taurolithocholic acid (sodium salt). This product is intended for research and analytical applications. Taurolithocholic acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and *LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium salt not only protects mice from lethal SFTSV* infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .

HY-150753

RS6212 1 Publications Verification	Oxidative Phosphorylation Lactate Dehydrogenase	Cancer
RS6212 is a specific *LDH* (lactate dehydrogenase) inhibitor with an IC₅₀ value of 12.03 μM . RS6212 inhibits tumor growth and exhibits potent anticancer activity in multiple cancer cell lines .

HY-179027

LDH-IN-5	Lactate Dehydrogenase Apoptosis Reactive Oxygen Species (ROS) SOD	Neurological Disease
LDH-IN-5 is a Lactate Dehydrogenase (LDH) inhibitor with neuroprotective activity. LDH-IN-5 can inhibit cell apoptosis, reduce ROS, MDA production and increases superoxide dismutase (SOD) activity. LDH-IN-5 can be used for the research of neurological disease, such as ischemic stroke .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W013032

Oxamic acid Maximum Cited Publications 58 Publications Verification Oxamidic acid	Microorganisms Source Classification	Lactate Dehydrogenase Apoptosis
Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .

HY-113308A

Taurolithocholic acid sodium salt 5+ Cited Publications	Structural Classification Animals Classification of Application Fields Metabolic Disease Disease Research Fields Steroids Source Classification	Calcium Channel Ferroptosis PI3K Reactive Oxygen Species (ROS) Akt HBV
Taurolithocholic acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and *LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium salt not only protects mice from lethal SFTSV* infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .

HY-113486

Lathosterol 2 Publications Verification	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite SOD Lactate Dehydrogenase
Lathosterol is a plant sterol and cholesterol-like molecule. Lathosterol increases antioxidant enzymes (such as SOD, CAT, and GSH) and decreases *LDH*. Lathosterol has a hepatoprotective effect on mice with acetaminophen (HY-66005)-induced liver injury ^{[1] .}

HY-N7393

Isomalt Palatinitol	other families Metabolic Disease Plants Disease Research Fields Saccharides Source Classification	Environmental Pollutants Lactate Dehydrogenase
Isomalt (Palatinitol), a well-tolerated, non-toxic polyol and a protein-stabilizing excipient, stabilizes lactate dehydrogenase (LDH) moderately during freeze-drying, and performs better during storage. Isomalt is traditionally used as a sweetening agent in the food industry and as a tabletting excipient for pharmaceutical purposes .

HY-N5073

Vitexin-4''-O-glucoside 4''-O-Glucosylvitexin	Cardiovascular Disease Structural Classification Flavonoids Classification of Application Fields Flavones Rosaceae Phenols Polyphenols Crataegus pinnatifida Bge. Plants Disease Research Fields Source Classification	JNK p38 MAPK Interleukin Related TNF Receptor Caspase Lactate Dehydrogenase Apoptosis
Vitexin-4''-O-glucoside (4''-O-Glucosylvitexin) is an orally active natural flavonoid component with multiple pharmacological effects including antioxidation, anti-inflammation, cytoprotection and anti-apoptosis. Vitexin-4''-O-glucoside regulates the MAPK signaling pathway by downregulating the phosphorylation levels of JNK and p38, thereby blocking endoplasmic reticulum stress responses. Vitexin-4''-O-glucoside alleviates oxidative stress by reducing MDA content and upregulating the activities of SOD and CAT, attenuates inflammation by downregulating the expressions of inflammatory factors TNF-α, IL-1β and IL-6, and also reduces *LDH* release and inhibits caspase-3 activation. Vitexin-4''-O-glucoside effectively improves drug-induced acute liver injury and exerts significant protective effects against myocardial hypoxia/reoxygenation injury. Vitexin-4''-O-glucoside can be used in studies on acute liver injury, cardiovascular diseases and myocardial hypoxia-reoxygenation injury .

HY-N2177

3-Dehydrotrametenolic acid	Triterpenes Classification of Application Fields Terpenoids Polyporaceae Poria cocos Plants Disease Research Fields Source Classification Cancer	Lactate Dehydrogenase Apoptosis
3-Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-Dehydrotrametenolic acid induces apoptosis and has anticancer activity .

HY-N16650

Bisadinrone A	Structural Classification Terpenoids Sesquiterpenes Plants Curcuma longa Source Classification Zingiberaceae	Lactate Dehydrogenase
Bisadinrone A is a sesquiterpene found in Curcuma longa. Bisadinrone A can inhibit *LDH* release and shows significant anti-myocardial ischemia-reperfusion injury activity. Bisadinrone A can be used for the research of cardiovascular disease, such as ischemic heart disease .

HY-N2891

Aristolactam A II Aristololactam A II	Piper longum Linn. Structural Classification Alkaloids Pyrrole Alkaloids Piperaceae Plants Source Classification	Parasite COX
Aristolactam A II (Aristololactam A II) is a weak COX inhibitor with cytotoxic and anti-plasmodial activities. Aristolactam A II exhibits inhibitory activity against Chloroquine (HY-17589A)-sensitive strains, and exerts its inhibitory effect on Plasmodium falciparum growth by inducing cell membrane damage marked by LDH release. Aristolactam A II can be applied to the research of malaria-related mechanisms .

HY-113308AR

Taurolithocholic acid sodium salt (Standard)	Structural Classification Animals Steroids Source Classification	Reference Standards Calcium Channel Ferroptosis PI3K Reactive Oxygen Species (ROS) Akt HBV
Taurolithocholic acid (sodium salt) (Standard) is the analytical standard of Taurolithocholic acid (sodium salt). This product is intended for research and analytical applications. Taurolithocholic acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and *LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium salt not only protects mice from lethal SFTSV* infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .

HY-N2638

Ilexsaponin A	Cardiovascular Disease Aquifoliaceae Triterpenes Classification of Application Fields Terpenoids Plants Disease Research Fields Tabernaemontana elegans Stapf Source Classification	Apoptosis
Ilexsaponin A, isolated from the root of Ilex pubescens, attenuates ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway. Ilexsaponin A can reduce myocardial infarct size, lower the serum levels of LDH, AST and CK-MB, increase cellular viability and inhibit apoptosis in hypoxia/reoxygenation cardiomyocytes .

HY-W013032R

Oxamic acid (Standard) Oxamidic acid (Standard)	Microorganisms Source Classification	Reference Standards Lactate Dehydrogenase Apoptosis
Oxamic acid (Standard) is the analytical standard of Oxamic acid. This product is intended for research and analytical applications. Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis[1][2][3].

HY-113486R

Lathosterol (Standard)	Structural Classification Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite Reference Standards SOD Lactate Dehydrogenase
Lathosterol (Standard) is the analytical standard of Lathosterol (HY-113486). This product is intended for research and analytical applications. Lathosterol is a plant sterol and cholesterol-like molecule. Lathosterol increases antioxidant enzymes (such as SOD, CAT, and GSH) and decreases *LDH*. Lathosterol has a hepatoprotective effect on mice with acetaminophen (HY-66005)-induced liver injury ^{[1] .}

HY-N7393R

Isomalt (Standard) Palatinitol (Standard)	other families Plants Saccharides Source Classification	Reference Standards Lactate Dehydrogenase
Isomalt (Standard) is the analytical standard of Isomalt. This product is intended for research and analytical applications. Isomalt (Palatinitol), a well-tolerated, non-toxic polyol and a protein-stabilizing excipient, stabilizes lactate dehydrogenase (LDH) moderately during freeze-drying, and performs better during storage. Isomalt is traditionally used as a sweetening agent in the food industry and as a tabletting excipient for pharmaceutical purposes .

HY-N2638R

Ilexsaponin A (Standard)	Aquifoliaceae Triterpenes Structural Classification Terpenoids Plants Tabernaemontana elegans Stapf Source Classification	Reference Standards Apoptosis
Ilexsaponin A (Standard) is the analytical standard of Ilexsaponin A. This product is intended for research and analytical applications. Ilexsaponin A, isolated from the root of Ilex pubescens, attenuates ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway. Ilexsaponin A can reduce myocardial infarct size, lower the serum levels of LDH, AST and CK-MB, increase cellular viability and inhibit apoptosis in hypoxia/reoxygenation cardiomyocytes .

HY-P3148

Astin B	Alkaloids Other Alkaloids Plants Compositae Erythrina latissima E. Mey. Source Classification	p62 Atg8/LC3 Apoptosis Autophagy Reactive Oxygen Species (ROS) JNK Bcl-2 Family Caspase
Astin B is a orally active and potent cyclic pentapeptide, that can be isolated from Aster tataricus. Astin B has hepatotoxic effects in vitro and in vivo and that hepatic injury was primarily mediated by apoptosis in a mitochondria/caspase-dependent manner. Astin B induces autophagy in L-02 cells, increases LC3-II and decreases p62 expression .

HY-N15378

β-Carotene-15,15'-epoxide	Structural Classification Natural Products Spondias mombin L. Plants Anacardiaceae Source Classification	IAP Bcl-2 Family COX TNF Receptor Caspase Apoptosis
β-carotene-15,15ʹ-epoxide is a XIAP antagonist with apoptosis-inducing and antitumor activity, found in the leaves of Spondias mombin. In a DMBA (HY-W011845)-induced rat model of breast cancer, β-carotene-15,15ʹ-epoxide binds to the BIR3 domain of the anti-apoptotic protein XIAP, blocking its interaction with caspase-9 and thereby promoting tumor cell apoptosis. In addition, β-carotene-15,15ʹ-epoxide significantly downregulates the expression of BCL-2, COX-2, and TNF-α in tumor tissues, reduces MDA levels, increases catalase activity, and modulates serum levels of LDH, ALP, and ALT, demonstrating strong antioxidant, anti-inflammatory, and metabolic protective effects. β-carotene-15,15ʹ-epoxide may be used in research on inflammation-related conditions and cancers such as breast cancer .

Cat. No.	Product Name	Chemical Structure

HY-113308S1

Taurolithocholic acid-d4

Taurolithocholic acid-d₄ is deuterium labeled Taurolithocholic acid. Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .

HY-113308AS1

Taurolithocholic Acid-d5 sodium salt

Taurolithocholic Acid-d₅ (sodium) is the deuterium labeled Taurolithocholic acid sodium salt. Taurolithocholic Acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic Acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic Acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic Acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic Acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic Acid sodium salt not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .

HY-W040073S

Nifurtimox-d4
Nifurtimox-d₄ is deuterium labeled Nifurtimox. Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).

HY-113486S1

lathosterol-d7
lathosterol-d₇ is deuterium labeled Lathosterol (HY-113486). Lathosterol is a plant sterol and cholesterol-like molecule. Lathosterol increases antioxidant enzymes (such as SOD, CAT, and GSH) and decreases *LDH*. Lathosterol has a hepatoprotective effect on mice with acetaminophen (HY-66005)-induced liver injury ^{^.}

HY-113308AS

Taurolithocholic acid-d4 sodium

Taurolithocholic acid-d₄ (sodium) is the deuterium labeled Taurolithocholic acid (sodium salt). Taurolithocholic acid sodium is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .

HY-113308AS2

Taurolithocholic acid-d4-1 sodium

Taurolithocholic acid-d₄-1 (sodium) is the deuterium labeled Taurolithocholic acid. Taurolithocholic acid sodium is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .

HY-113308S

Taurolithocholic acid-d5

Taurolithocholic acid-d₅ is deuterium labeled Taurolithocholic acid. Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks